Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma

Melanoma Research

Volumn 26, Issue 5, 2016, Pages 429-441

  Enninga, Elizabeth Ann L ^a   Nevala, Wendy K ^a   Holtan, Shernan G ^b   Leontovich, Alexey A ^a   Markovic, Svetomir N ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

galectin 9; immunity; macrophage; melanoma; T cell immunoglobulin and mucin domain containing 3

Indexed keywords

BINDING PROTEIN; ECALECTIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; T LYMPHOCYTE IMMUBOGLOBULIN AND MUCIN DOMAIN CONTAINING 3 BINDING PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; GALECTIN;

ADVANCED CANCER; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER PATIENT; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IN VITRO STUDY; MACROPHAGE; MAJOR CLINICAL STUDY; METASTATIC MELANOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; TH1 CELL; TH2 CELL; TUMOR IMMUNITY; FEMALE; IMMUNOLOGY; MALE; MELANOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; SKIN TUMOR; SURVIVAL ANALYSIS;

CELL DIFFERENTIATION; FEMALE; GALECTINS; HUMANS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TH2 CELLS;

EID: 84979609119     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000281     Document Type: Article

References (50)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
2. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-330.
3. Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, Markovic SN. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res 2009; 15:1931-1939.
4. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436-444.
5. Brasanac D, Markovic-Lipkovski J, Hadzi-Djokic J, Muller GA, Muller CA. Immunohistochemical analysis of HLA class II antigens and tumor infiltrating mononuclear cells in renal cell carcinoma: Correlation with clinical and histopathological data. Neoplasma 1999; 46:173-178.
6. Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+ ) T cell responses against MAGE-6 in HLA-DRB10401(+ ) patients with renal cell carcinoma or melanoma. J Exp Med 2002; 196:619-628.
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
8. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550.
9. Rabinovich GA, Toscano MA. Turning 'sweet' on immunity: Galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009; 9:338-352.
10. Yang RY, Rabinovich GA, Liu FT. Galectins: Structure, function and therapeutic potential. Expert Rev Mol Med 2008; 10:e17.
11. Katoh S, Ishii N, Nobumoto A, Takeshita K, Dai SY, Shinonaga R, et al. Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am J Respir Crit Care Med 2007; 176:27-35.
12. Dardalhon V, Anderson AC, Karman J, Apetoh L, Chandwaskar R, Lee DH, et al. Tim-3/galectin-9 pathway: Regulation of Th1 immunity through promotion of CD11b + Ly-6G + myeloid cells. J Immunol 2010; 185:1383-1392.
13. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6:1245-1252.
14. Hastings WD, Anderson DE, Kassam N, Koguchi K, Greenfield EA, Kent SC, et al. TIM-3 is expressed on activated human CD4 + T cells and regulates Th1 and Th17 cytokines. Eur J Immunol 2009; 39:2492-2501.
15. Meggyes M, Miko E, Polgar B, Bogar B, Farkas B, Illes Z, et al. Peripheral blood TIM-3 positive NK and CD8 + T cells throughout pregnancy: TIM-3/ galectin-9 interaction and its possible role during pregnancy. PLoS One 2014; 9:e92371.
16. Meggyes M, Lajko A, Palkovics T, Totsimon A, Illes Z, Szereday L, et al. Fetomaternal immune regulation by TIM-3/galectin-9 pathway and PD-1 molecule in mice at day 14.5 of pregnancy. Placenta 2015; 36:1153-1160.
17. Holtan SG, Creedon DJ, Haluska P, Markovic SN. Cancer and pregnancy: Parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc 2009; 84:985-1000.
18. Enninga EA, Holtan SG, Creedon DJ, Dronca RS, Nevala WK, Ognjanovic S, et al. Immunomodulatory effects of sex hormones: Requirements for pregnancy and relevance in melanoma. Mayo Clin Proc 2014; 89:520-535.
19. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002; 8:793-800.
20. Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol 2015; 67 (Pt A):4-17.
21. Kottschade LA, Suman VJ, Amatruda T 3rd, McWilliams RR, Mattar BI, Nikcevich DA, et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group Study, N057E(1). Cancer 2011; 117:1704-1710.
22. Kottschade LA, Suman VJ, Perez DG, McWilliams RR, Kaur JS, Amatruda TT 3rd, et al. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group study, N0775. Cancer 2013; 119:586-592.
23. Holtan SG, Mansfield AS, Creedon DJ, Nevala WK, Haluska P, Leontovich AA, et al. An organ system based approach to prognosis in advanced melanoma. Front Biosci (Elite Ed) 2012; 4:2823-2833.
24. Genin M, Clement F, Fattaccioli A, Raes M, Michiels C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer 2015; 15:577.
25. Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis. Neuro Oncol 2004; 6:227-235.
26. Anderson CF, Mosser DM. A novel phenotype for an activated macrophage: The type 2 activated macrophage. J Leukoc Biol 2002; 72:101-106.
27. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207:2187-2194.
28. Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res 2011; 17:1915-1923.
29. Kageshita T, Kashio Y, Yamauchi A, Seki M, Abedin MJ, Nishi N, et al. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer 2002; 99:809-816.
30. Su EW, Bi S, Kane LP. Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology 2011; 21:1258-1265.
31. Wu C, Thalhamer T, Franca RF, Xiao S, Wang C, Hotta C, et al. Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. Immunity 2014; 41:270-282.
32. Cordero JB, Macagno JP, Stefanatos RK, Strathdee KE, Cagan RL, Vidal M. Oncogenic ras diverts a host TNF tumor suppressor activity into tumor promoter. Dev Cell 2010; 18:999-1011.
33. Saijo Y, Tanaka M, Miki M, Usui K, Suzuki T, Maemondo M, et al. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: In vivo analysis of tumorstromal interaction. J Immunol 2002; 169:469-475.
34. Yoshida H, Imaizumi T, Kumagai M, Kimura K, Satoh C, Hanada N, et al. Interleukin-1beta stimulates galectin-9 expression in human astrocytes. Neuroreport 2001; 12:3755-3758.
35. Arikawa T, Watanabe K, Seki M, Matsukawa A, Oomizu S, Sakata KM, et al. Galectin-9 ameliorates immune complex-induced arthritis by regulating Fc gamma R expression on macrophages. Clin Immunol 2009; 133:382-392.
36. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25:677-686.
37. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005; 175:342-349.
38. Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 2011; 9:216.
39. Zhang B, Yao G, Zhang Y, Gao J, Yang B, Rao Z. M2-polarized tumorassociated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (Sao Paulo) 2011; 66:1879-1886.
40. Petrillo M, Zannoni GF, Martinelli E, pedone Anchora L, Ferrandina G, Tropeano G, et al. Polarisation of tumor-associated macrophages toward M2 phenotype correlates with poor response to chemoradiation and reduced survival in patients with locally advanced cervical cancer. PLoS One 2015; 10:e0136654.
41. Matsuura A, Tsukada J, Mizobe T, Higashi T, Mouri F, Tanikawa R, et al. Intracellular galectin-9 activates inflammatory cytokines in monocytes. Genes Cells 2009; 14:511-521.
42. Roszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm 2015; 2015:1-16.
43. Edwards JP, Zhang X, Frauwirth KA, Mosser DM. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol 2006; 80:1298-1307.
44. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011; 71:3540-3551.
45. Sabatos CA, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, Zheng XX, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 2003; 4:1102-1110.
46. Nakayama M, Akiba H, Takeda K, Kojima Y, Hashiguchi M, Azuma M, et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 2009; 113:3821-3830.
47. Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(+ ) T cells induced by melanoma vaccines. Cancer Res 2014; 74:1045-1055.
48. Baghdadi M, Nagao H, Yoshiyama H, Akiba H, Yagita H, Dosaka-Akita H, et al. Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Cancer Immunol Immunother 2013; 62:629-637.
49. Liu FT, Rabinovich GA. Galectins: Regulators of acute and chronic inflammation. Ann N Y Acad Sci 2010; 1183:158-182.
50. Stillman BN, Hsu DK, Pang M, Brewer CF, Johnson P, Liu FT, et al. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol 2006; 176:778-789.